# Clarity Pharmaceuticals

Source: https://onco.cc/companies/clarity-pharmaceuticals/  
OnCo record `clarity-pharmaceuticals` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Clarity Pharmaceuticals, a Sydney radiopharmaceutical company, pairs copper isotopes with SAR-bisPSMA, a molecule that binds PSMA on prostate cancer cells: copper-64 for PET imaging, in the phase 3 AMPLIFY and CLARIFY trials, and copper-67 for therapy in the SECuRE trial. The copper-67 therapy is still at the dose-finding stage.

## Summary

Co-PSMA head-to-head data (EAU 2026) showed Cu-64 SAR-bisPSMA more than doubled lesion and patient detection versus Ga-68 PSMA-11; FDA Fast Track in biochemical recurrence; commercial manufacturing agreement with Nucleus RadioPharma (April 2026). SECuRE therapy trial: 7 of 19 patients at 8 GBq 67Cu reached complete response or undetectable disease (July 2026).

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Sydney
- Type: radiopharma
- Website: https://www.claritypharmaceuticals.com
- Ticker: CU6.AX

## Sources

- SECuRE update: https://www.prnewswire.com/news-releases/clarity-pharmaceuticals-announces-secure-trial-update-on-8-gbq-67cu-sar-bispsma-dose-level-with-two-additional-complete-responses-302843184.html

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Imaging](https://onco.cc/fronts/imaging/), [Radiopharmaceuticals & Theranostics](https://onco.cc/fronts/radiopharma/)
- technologies: [PSMA PET](https://onco.cc/technologies/psma-pet/), [Radioligand therapy (beta emitters)](https://onco.cc/technologies/radioligand-therapy/)
- targets: [PSMA](https://onco.cc/targets/psma/)
- terms: [Theranostics](https://onco.cc/terms/theranostics/)
- trials: [64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)](https://onco.cc/trials/nct04868604/), [64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer](https://onco.cc/trials/nct06970847/), [Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy](https://onco.cc/trials/nct06056830/)

---
JSON: https://onco.cc/api/v1/entities/clarity-pharmaceuticals.json